10-K/A: TherapeuticsMD Files Amended 10-K to Include Omitted Information

TherapeuticsMD files an amendment to its annual report to include information previously omitted regarding directors, executive compensation, and related matters.

Summary

• TherapeuticsMD has filed an amendment to its original Form 10-K to include information that was previously omitted.
• The amendment includes details about the company's directors, executive officers, corporate governance, executive compensation, security ownership, related party transactions, and principal accountant fees.
• The original Form 10-K was filed on March 29, 2024, and this amendment is being filed because the company does not expect to file its definitive proxy statement within 120 days of the fiscal year end.
• The company is also filing new certifications from its CEO and CFO related to this filing.
• This amendment does not include any new financial statements or modify any disclosures related to internal controls.
• As of April 19, 2024, there were 11,532,443 shares of common stock outstanding.
• The aggregate market value of voting and non-voting common equity held by non-affiliates was $34,439,072 as of June 30, 2023.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, and while it addresses some governance and compensation matters, it does not contain any significant positive or negative news. The need for an amendment is slightly negative, but the overall tone is neutral.

Positives

• The company has a majority of independent directors on its board.
• The company has established committees for audit and compensation, ensuring oversight.
• The company has a clawback policy for incentive compensation.
• The company has policies in place to prevent hedging and pledging of company securities by insiders.
• The company has a clear process for director nominations and evaluations.
• The company has a policy to ensure fair related party transactions.

Negatives

• The company had to file an amendment to its annual report due to omitted information.
• The company does not expect to file its definitive proxy statement within 120 days of the fiscal year end.
• The company has a relatively small board of directors.
• The company has a history of using consulting agreements for key financial roles.

Risks

• The company faces operational, economic, financial, legal, regulatory, and competitive risks.
• The company's reliance on consulting agreements for key financial roles could pose a risk if those agreements are terminated.
• The company's financial performance is subject to various market and economic conditions.
• The company's compensation policies could create undue risk if not managed properly.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Management Comments

• The company does not expect to file its definitive proxy statement within 120 days of the end of its most recent fiscal year.
• The company is filing this Form 10-K/A in order to include information that would have been contained in the definitive proxy statement into the Original Form 10-K.

Industry Context

This filing is a standard regulatory requirement for publicly traded companies. The details provided about the board, compensation, and related transactions are typical for a company of this size and structure. The company's transition to a pharmaceutical royalty company is a significant shift that is not fully detailed in this document.

Comparison to Industry Standards

• The board composition, with a majority of independent directors, aligns with Nasdaq listing requirements and is a common practice among publicly traded companies.
• The compensation structure for executives, including base salary, bonuses, and equity awards, is typical for companies in the pharmaceutical industry.
• The use of consulting agreements for key financial roles is not uncommon, especially during transitions or for smaller companies, but it can be a point of risk.
• The level of detail provided in the related party transactions is consistent with SEC disclosure requirements.
• The audit fees paid to Berkowitz Pollack Brant and Grant Thornton are within the range of what is expected for a company of this size, although the change in auditors is notable.

Management Changes

Related Party Transactions

• The company entered into subscription agreements with Rubric Capital Management LP, resulting in the issuance of common stock and the redemption of preferred stock.
• The company paid certain affiliates of Rubric approximately $3.0 million as a make-whole payment.
• The company issued and sold 312,525 shares of Common Stock to Rubric at a price per share equal to $3.6797.
• Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal to $2.2761.

Stakeholder Impact

• Shareholders are provided with additional information about the company's governance, compensation, and ownership structure.
• Employees are indirectly impacted by the details of executive compensation and the company's overall financial health.
• The company's suppliers and creditors are indirectly impacted by the company's financial performance and governance practices.

Next Steps

• The company will need to file its definitive proxy statement for its upcoming annual stockholders meeting.
• The company will continue to operate under its current board and management structure.
• The company will continue to comply with SEC and Nasdaq regulations.

Key Dates

Keywords

TherapeuticsMD, Form 10-K/A, amendment, directors, executive compensation, corporate governance, audit committee, compensation committee, related party transactions, stock ownership, financial reporting, Rubric Capital Management, Berkowitz Pollack Brant, Grant Thornton